EYEN vs. ACXP, ALRN, SLGL, FBRX, ENLV, UBX, APM, SNSE, VIRX, and DRRX
Should you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include Acurx Pharmaceuticals (ACXP), Aileron Therapeutics (ALRN), Sol-Gel Technologies (SLGL), Forte Biosciences (FBRX), Enlivex Therapeutics (ENLV), Unity Biotechnology (UBX), Aptorum Group (APM), Sensei Biotherapeutics (SNSE), Viracta Therapeutics (VIRX), and DURECT (DRRX). These companies are all part of the "pharmaceutical preparations" industry.
Eyenovia (NASDAQ:EYEN) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.
25.8% of Eyenovia shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 7.8% of Eyenovia shares are owned by insiders. Comparatively, 35.3% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Eyenovia. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 1 mentions for Eyenovia. Acurx Pharmaceuticals' average media sentiment score of 0.55 beat Eyenovia's score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.
Eyenovia currently has a consensus target price of $10.00, suggesting a potential upside of 1,783.59%. Acurx Pharmaceuticals has a consensus target price of $12.00, suggesting a potential upside of 463.38%. Given Eyenovia's higher probable upside, research analysts clearly believe Eyenovia is more favorable than Acurx Pharmaceuticals.
Eyenovia's return on equity of -213.33% beat Acurx Pharmaceuticals' return on equity.
Eyenovia has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.9, meaning that its share price is 290% less volatile than the S&P 500.
Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
Eyenovia received 159 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 90.91% of users gave Acurx Pharmaceuticals an outperform vote while only 65.00% of users gave Eyenovia an outperform vote.
Summary
Eyenovia beats Acurx Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Eyenovia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyenovia Competitors List
Related Companies and Tools
